
- /
- Supported exchanges
- / SHE
- / 300601.SHE
Shenzhen Kangtai Biological Products Co Ltd (300601 SHE) stock market data APIs
Shenzhen Kangtai Biological Products Co Ltd Financial Data Overview
Shenzhen Kangtai Biological Products Co., Ltd. researches and develops, produces, and sells various types of human vaccines in China. Its marketed vaccines include SARS-COV-2 vaccines, HIB conjugate vaccines, 13-valent pneumococcal conjugate vaccines, recombinant hepatitis B vaccines, 23-valent pneumococcal polysaccharide vaccines, diphtheria tetanus acellular pertussis and haemophilus influenzae type b combined vaccines, cell-free whitebait b-type haemophilus influenzae combined vaccines, and measles and rubella combined vaccines. The company's research and development vaccines comprise rabies vaccine for human use, inactivated poliomyelitis vaccine, and live attenuated varicella vaccine. Shenzhen Kangtai Biological Products Co., Ltd. was founded in 1992 and is headquartered in Shenzhen, China.
Why to choose EODHD?
Prices start at $19.99
24/7 Live support
Robust, powerful and reliable data
API Simplicity of a few lines of code
Or get access to advanced financial data starting only $19.99
Get Shenzhen Kangtai Biological Products Co Ltd data using free add-ons & libraries
Get Shenzhen Kangtai Biological Products Co Ltd Fundamental Data
Shenzhen Kangtai Biological Products Co Ltd Fundamental data includes:
- Net Revenue: 2 845 M
- EBITDA: 444 M
- Earnings Per Share: 0
- Income Statements
- Balance Sheets
- Cash flows
Plans with Fundamental data
Starting from
End-of-day & Earnings data
Get Shenzhen Kangtai Biological Products Co Ltd Earnings data
What’s included:
- Latest Release: 2025-04-20
- EPS/Forecast: 0.08
Get Shenzhen Kangtai Biological Products Co Ltd End-of-day data
EOD Historical Data package for
What’s included:
- End of Day, Intraday and Live APIs
- Splits
- Dividends
Shenzhen Kangtai Biological Products Co Ltd News

Cooperation Agreement Concluded between BioKangtai and Biotis
-- Indicating Technology Transfer of the World's First Dual-carrier 13-valent Pneumococcal Conjugate Vaccine to Indonesia SHENZHEN, China, April 7, 2023 /PRNewswire/ -- On the morning of April 5, Be...


Licensing and Agency Agreement Signed between Beijing Minhai (Biokangtai) and Phil. Pharmawealth, Inc.
Marks the First Entry of Biokangtai's 13-valent Pneumococcal Vaccine into Southeast Asian Market SHENZHEN, China, Aug. 31, 2022 /PRNewswire/ -- On August 30, Beijing Minhai Biotechnology Co., Ltd. h...

BIOKANGTAI Signs a Cooperation Agreement with the Largest Importer of Parenteral Products in Philippines
BIOKANGTAI's 23-valent pneumonia vaccine will enter the Southeast Asian market for the first time SHENZHEN, China, March 21, 2022 /PRNewswire/ -- On March 17, 2022, Shenzhen Kangtai Biological Produc...

Kangtai Adenovirus Vector COVID-19 Vaccine (KCONECAVAC) Exported for the First Time
Actively Explore Overseas Markets to Increase Vaccine Accessibility SHENZHEN, China, Nov. 19, 2021 /PRNewswire/ -- At 3 a.m. on November 19, the first batch of more than 4 million doses of adenovirus...
Or get access to advanced financial data starting only $19.99
- Flexibility: No long-term commitments, just a minimum of one month
- Instant access: Get your API key and instructions within seconds of subscribing
- Price stability: Locked-in rates for subscribed users, never changing
What’s included:
- API Calls per Day: 100 000/day
- API Requests per Min.: 1000/minute
- Type of Usage: Personal use
Data access:
Historical EOD, Fundamental, Real-Time, Intraday, Live (Delayed), Technical & Screener APIs, News Feed, 40 000 Stock Logos and many more. See a full list.